Ankit Mahadevia
CEO and President at Spero Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Spero Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Spero Therapeutics Inc. October 5, 202399.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 28, 2025 | Spero Therapeutics Inc. | Open-market sale | −6,572 | $1.97 | $12,947 |
| Jun 12, 2025 | Spero Therapeutics Inc. | Grant or award | +20,000 | — | — |
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −13,959 | $0.78 | $10,888 |
| Feb 5, 2025 | Spero Therapeutics Inc. | Open-market sale | −55,260 | $0.78 | $43,103 |
| Aug 27, 2024 | Spero Therapeutics Inc. | Open-market sale | −5,912 | $1.35 | $7,981 |
| May 29, 2024 | Spero Therapeutics Inc. | Grant or award | +20,000 | — | — |
| Feb 2, 2024 | Spero Therapeutics Inc. | Open-market sale | −63,795 | $1.37 | $87,399 |
| Oct 5, 2023 | Spero Therapeutics Inc. | Grant or award | +20,000 | — | — |
| Aug 28, 2023 | Spero Therapeutics Inc. | Open-market sale | −9,040 | $1.26 | $11,390 |
| Feb 3, 2023 | Spero Therapeutics Inc. | Open-market sale | −12,286 | $1.81 | $22,238 |
| Feb 1, 2023 | Spero Therapeutics Inc. | Grant or award | +531,914 | — | — |
Questions about Ankit Mahadevia
What boards is Ankit Mahadevia on?
Ankit Mahadevia sits on the board of Spero Therapeutics Inc.
What company is Ankit Mahadevia the CEO of?
Ankit Mahadevia is CEO and President of Spero Therapeutics Inc.
How long has Ankit Mahadevia served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.